US 12,286,469 B2
Humanized antibodies binding to amyloid-beta (A-beta)
Neil R. Cashman, Vancouver (CA); Steven S. Plotkin, Vancouver (CA); Johanne Kaplan, Sherborn, MA (US); Judith Maxwell Silverman, Whistler (CA); and Ebrima Gibbs, Port Moody (CA)
Assigned to The University of British Columbia; and ProMIS Neurosciences Inc.
Appl. No. 16/631,676
Filed by THE UNIVERSITY OF BRITISH COLUMBIA, Vancouver (CA); and PROMIS NEUROSCIENCES INC., Toronto (CA)
PCT Filed Jul. 18, 2018, PCT No. PCT/CA2018/050875
§ 371(c)(1), (2) Date Jan. 16, 2020,
PCT Pub. No. WO2019/014768, PCT Pub. Date Jan. 24, 2019.
Claims priority of provisional application 62/622,126, filed on Jan. 25, 2018.
Claims priority of application No. PCT/CA2017/050866 (WO), filed on Jul. 18, 2017.
Prior Publication US 2020/0181247 A1, Jun. 11, 2020
This patent is subject to a terminal disclaimer.
Int. Cl. A61K 39/395 (2006.01); A61K 39/00 (2006.01); A61K 51/10 (2006.01); A61P 25/28 (2006.01); C07K 16/00 (2006.01); C07K 16/18 (2006.01); G01N 33/68 (2006.01)
CPC C07K 16/18 (2013.01) [A61K 51/1018 (2013.01); A61P 25/28 (2018.01); G01N 33/6896 (2013.01); A61K 2039/505 (2013.01); C07K 2317/00 (2013.01); C07K 2317/24 (2013.01); C07K 2317/30 (2013.01); C07K 2317/31 (2013.01); C07K 2317/50 (2013.01); C07K 2317/51 (2013.01); C07K 2317/515 (2013.01); C07K 2317/54 (2013.01); C07K 2317/55 (2013.01); C07K 2317/56 (2013.01); C07K 2317/565 (2013.01); C07K 2317/569 (2013.01); C07K 2317/60 (2013.01); C07K 2317/62 (2013.01); C07K 2317/622 (2013.01); C07K 2317/624 (2013.01); C07K 2317/626 (2013.01); C07K 2317/64 (2013.01); C07K 2317/66 (2013.01); C07K 2317/76 (2013.01); C07K 2317/92 (2013.01); G01N 2333/4709 (2013.01)] 22 Claims
 
1. A humanized antibody or antigen binding fragment thereof that binds amyloid-beta (A-beta) comprising:
a heavy chain variable region comprising the amino acid sequence of SEQ ID NO: 44 and a light chain variable region comprising the amino acid sequence of SEQ ID NO: 64;
a heavy chain variable region comprising the amino acid sequence of SEQ ID NO: 44 and a light chain variable region comprising the amino acid sequence of SEQ ID NO: 66;
a heavy chain variable region comprising the amino acid sequence of SEQ ID NO: 44 and a light chain variable region comprising the amino acid sequence of SEQ ID NO: 68;
a heavy chain variable region comprising the amino acid sequence of SEQ ID NO: 46 and a light chain variable region comprising the amino acid sequence of SEQ ID NO: 64;
a heavy chain variable region comprising the amino acid sequence of SEQ ID NO: 46 and a light chain variable region comprising the amino acid sequence of SEQ ID NO: 66;
a heavy chain variable region comprising the amino acid sequence of SEQ ID NO: 46 and a light chain variable region comprising the amino acid sequence of SEQ ID NO: 68;
a heavy chain variable region comprising the amino acid sequence of SEQ ID NO: 48 and a light chain variable region comprising the amino acid sequence of SEQ ID NO: 64;
a heavy chain variable region comprising the amino acid sequence of SEQ ID NO: 48 and a light chain variable region comprising the amino acid sequence of SEQ ID NO: 66;
a heavy chain variable region comprising the amino acid sequence of SEQ ID NO: 48 and a light chain variable region comprising the amino acid sequence of SEQ ID NO: 68;
a heavy chain variable region comprising the amino acid sequence of SEQ ID NO: 50 and a light chain variable region comprising the amino acid sequence of SEQ ID NO: 68; or
a heavy chain variable region comprising the amino acid sequence of SEQ ID NO: 52 and a light chain variable region comprising the amino acid sequence of SEQ ID NO: 68.